TP53-dependence on the effect of doxorubicin and Src inhibitor combination therapy. Issue 8 (August 2018)

• Record Type: Journal Article
• Authors: Lee, Yun Sun; Choi, Ji-Yoon; Lee, Jeeyun; Shim, Da Mi; Kim, Jaesoo; Park, Woong-Yang; Nam, Do-Hyun; Seo, Sung Wook
• Is Part Of: Tumor biology. Volume 40:Issue 8(2018)
• Publication Date: 2018-08
• Subjects: TP53 -- Src kinase -- doxorubicin -- drug resistant -- saracatinib (AZD0530); Cancer -- Periodicals; Oncology -- Periodicals; Tumors -- Periodicals; 616.994
• DOI: 10.1177/1010428318794217
• Languages: English
• ISSNs: 1010-4283

Abstract

The anticancer effects of Src kinase inhibitors are controversial. This study found an association between alterations in the TP53 gene and the synergy score for combination treatment with doxorubicin and an Src kinase inhibitor using human osteosarcoma cell lines (MG63 and U2OS) and human colon cancer cell line. Doxorubicin was found to activate signal transducer and activator of transcription 3 via Src kinase in cancer cells harboring alterations in TP53. A drug combination study using patient-derived cells confirmed that an Src kinase inhibitor synergizes with doxorubicin in cancer cells harboring alterations in TP53, while antagonizing its effect in cancer cells expressing wild-type TP53. Our findings suggest that genetic alterations in TP53 are a critical factor in determining the use of a combination treatment of doxorubicin and Src inhibitors.